Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study for its novel anti-microbial agent MRX-4, used in combination with contezolid (MRX-I), as a sequential treatment for diabetic foot infection in China.
Global Multi-Center Phase III Study Design and Approval
The global multi-center, randomized, double-blind Phase III study, which received approval in the European Union in December 2022, is designed to assess the safety and efficacy of the MRX-4 and contezolid combination in treating moderate or severe diabetic foot infection compared to the linezolid injection and oral preparation. The first patient was dosed in the US in May of the previous year.
In-House Developed New-Generation Oxazolidinone Antibiotics
Both contezolid and MRX-4 are in-house developed new-generation oxazolidinone antibiotics by MicuRx Pharmaceuticals. Contezolid was approved in China in June 2021 for the treatment of complex skin and soft tissue infections. MRX-4 is the pro-drug version of contezolid (MRX-1), known as contezolid acefosamil, and is a potent oxazolidinone antibiotic effective against Gram-positive pathogens.-Fineline Info & Tech
